Resmed Reports Q1 FY27 Revenue Growth, Higher Margins and EPS
Q1 FY27 core constant-currency revenue rose 7% year over year, non-GAAP gross margin increased, and non-GAAP EPS rose 14%. The board declared a $0.66 quarterly dividend, with a Nov. 12, 2026 record date.
Story updates
08:11:53 PM UTC
SquawkNews
Oct 29 (Reuters) - Resmed Q1 adjusted gross margin 62.5%.